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Available online 2 March 2019Background: Acute T-cell mediated rejection (TCMR) is usually indicated by alteration in serum-creatinine
measurements when considerable transplant damage has already occurred. There is, therefore, a need for
non-invasive early detection of immune signals that would precede the onset of rejection, prior to transplant
damage.
Methods: We examined the RT-qPCR expression of 22 literature-based genes in peripheral blood samples from
248 patients in the Kidney Allograft Immune Biomarkers of Rejection Episodes (KALIBRE) study. To account for
post-transplantation changes unrelated to rejection, we generated time-adjusted gene-expression residuals
from linear mixed-effects models in stable patients. To select genes, we used penalised logistic regression
based on 27 stable patients and 27 rejectors with biopsy-proven T-cell-mediated rejection, fulfilling strict inclu-
sion/exclusion criteria. We validated this signature in i) an independent group of stable patients and patients
with concomitant T-cell and antibody-mediated-rejection, ii) patients from an independent study, iii) cross-
sectional pre-biopsy samples from non-rejectors and iv) longitudinal follow-up samples covering the first
post-transplant year from rejectors, non-rejectors and stable patients.
Findings: A parsimonious TCMR-signature (IFNG, IP-10, ITGA4, MARCH8, RORc, SEMA7A, WDR40A) showed cross-
validated area-under-ROC curve 0.84 (0.77–0.88) (median, 2.5th–97.5th centile of fifty cross-validation cycles),
sensitivity 0.67 (0.59–0.74) and specificity 0.85 (0.75–0.89). The estimated probability of TCMR increased
sevenweeks prior to the diagnostic biopsy and decreased after treatment. Gene expression in all patients showed
pronounced variability, with up to 24% of the longitudinal samples in stable patients being TCMR-signature pos-
itive. In patients with borderline changes, up to 40% of pre-biopsy samples were TCMR-signature positive.aramit Chowdhury, Renal Unit, Guy's and St Thomas' NSHFoundation Trust, GreatMaze Pond, London SE1 9RT, UnitedKingdom;
rnandez-Fuentes), Paramit.Chowdhury@gstt.nhs.uk (P. Chowdhury).
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572 S. Christakoudi et al. / EBioMedicine 41 (2019) 571–583Interpretation: Molecular marker alterations in blood emerge well ahead of the time of clinically overt TCMR.
Monitoring a TCMR-signature in peripheral blood could unravel T-cell-related pro-inflammatory activity and
hidden immunological processes. This additional information could support clinical management decisions in
cases of patients with stable but poor kidney function or with inconclusive biopsy results.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).AbbreviationsGranzyme B, Perforin, Fas-ligand, FoxP3 and CXCL10 and interleu-BMR antibody mediated rejection
kins. However, single genes have lacked the sensitivity and spec-R acute rejection
ificity to translate early acute rejection detection into clinicalUC area under the ROC curve
practice. In urine, a three-gene signature has been found whichTG anti-thymocyte globuline
was also able to predict the clinical episode by some weeks. InTS American Transplantation Society
blood microarray studies have identified gene-sets capable ofKVN BK-virus nephropathy
distinguishing acute rejection. These, however, have not beenTS British Transplantation Society
analysed in a serial fashion to allow for determination of their pre-V.AUC cross-validated AUC
dictive value and they do not examine the effects of anti-rejectionGFR estimated glomerular filtration rate
therapy. In cardiac transplantation a commercially available 11SOT European Society of Organ Transplantation
gene set has been shown to reduce the need to perform biopsiesLMM generalised linear mixed-effects models
and led to greater patient satisfaction.LA Human Leucocyte AntigenMost recently, the multi-centre AART study from the US hasimmunosuppression
identified a 17 gene set in blood with an AUC of 0.94 and show aTR kidney transplant recipients
predictive value up to 3 months before detection by biopsy, butarsimonious
further clinical validation is still awaiting.The answer that makes the fewest assumptions; in
this manuscript the smallest set of genes showing
a satisfactory predictive performanceAdded value of this studyB peripheral blood
OC receiver operator characteristics curveThis is the first European study to comprehensively analyse serialT-qPCR Real time – quantitative Polymerase Chain Reaction
blood samples from renal transplant recipients.We collected sam-Cr Serum Creatinine
ples from 450 consecutive adult recipients at regular intervalsCMR T cell mediated Rejection
over their first year post-transplant. This has allowed us to per-TS The Transplantation SocietyT
form both cross sectional and longitudinal analysis. Patients se-
lected for the discovery phase all received a similar anti-rejection
protocol. Importantly this included induction therapy with an IL-
2R blocking antibody (Basiliximab) rather than a lymphocyte de-ignificant risk of trans-
ment therapy or hav-
from HLA variants
re responsible for kid-
fied thus far.
e number of patients
of their kidney func-
ipheral samples from
w surveillance of im-
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y focused on PubMed
ation received in and
ATC, ESOT and TTS)
groups has been pre-
ecipients have identi-
samples which corre-
ich are involved in
fficking. These include
pleting antibody, the latter being more common practice in the
US. Given that some of the genes are lymphocyte expressed,
the induction agent might have a significant effect on lymphocyte
gene expression,whichwe have observed. In longitudinal analysis
we have demonstrated for the first time the significant intra pa-
tient variability over time and a relationship to changes in anti-
rejection therapy. Here we describe a parsimonious (the one that
makes the fewest assumptions) T cell mediated rejection
(TCMR) signature using the expression of seven genes in periph-
eral blood.
We have also been able to demonstrate the predictive value of our
signature, with detection of acute rejection demonstrable up to
two months before the clinical event. We have subsequently car-
ried out validation in a separate cohort of patients. All in all the
number of samples analysed throughout our study nearly doubles
the numbers of samples used in the AART study, including there-
fore a more comprehensive longitudinal picture of the gene
measurements.
In order to assist the differential diagnosis with BK-virus nephrop-
athy (BKVN), which has the same clinical presentation as T cell
mediated rejection (TCMR), but requires the opposite therapy,
namely immunosuppression reduction, we have additionally de-
veloped a six-gene signature of BKVN. Further, we have examined
patientswith alternative induction regimens. Patients treatedwith
Rituximab showed similar gene-expression patterns to patients
treated with Basiliximab, whilst patients receiving Alemtuzumab
treatment showed both, high TCMR and high BKVN positivity.
Implications of all the available evidence
Information from gene expression in peripheral blood samples
from transplant recipients could provide valuable information to
clinicians for more personalised management and finally provide
some information on the recipient's immune status.
Potential benefits include earlier detection and treatment of acute
rejection aswell as separation from other causes of graft dysfunc-
tion, somethingwhich the presently used non-invasivemonitoring
tool, namely serum creatinine is unable to do. It may also allow re-
duction of anti-rejection therapy in other patients, minimising side
effects, that may further allow personalised precision medicine.
A trial of these biomarkers for evaluation in clinical practice is now
needed.
We believe the potential of the analysis strategy we applied could
be used in other biomarker signatures where longitudinal evalua-
tion is critical and this warrants the scrutiny by the wider
readership.
Fig. 1. Flow diagram of patients from the KALIBRE study. Biopsy categories were defined accord
UK); KCH – King's College Hospital NHS Foundation Trust (London, UK);K&C – East Kent Hosp
tibody-mediated rejection (category 2); TCMR – T-cell-mediated rejection (category 4);Mixed
with a specialised histological staining); unless specifically indicated, patients received Basilixim
BKVN for the discovery dataset are listed in Table 1; n – number of patients; s – number of samp
was used as representative for each stable patient in the signature development and cross-sec
573S. Christakoudi et al. / EBioMedicine 41 (2019) 571–5831. Introduction
Kidney transplantation remains the optimal treatment for patients
with end-stage kidney disease but requires life-long anti-rejection ther-
apy, which is a major contributor to morbidity and mortality in kidney
transplant recipients (KTRs). Balancing the level of immune suppression
in each recipient remains a major challenge, and occurs in a reactive
fashion in response to clinical events.
Monitoring of allograft function presently relies on serum creatinine
(SCr) values. SCr is not a sensitive marker, as it often changes only after
a considerable graft damage, and is not a specific marker either, as it
canbeaffectedby several factors other than rejectionandpatients further
require a percutaneous biopsy to diagnose the cause of transplant dys-
function. A biopsy, however, is an invasive procedure carrying risks and,
being prone to sampling error, could potentially fail to adequately un-
cover the cause of transplant dysfunction, with many cases reported as
“borderline suspicious for acute cellular rejection” [1]. Further, a biopsy
is usually carried out only when there is clear evidence of transplant
dysfunction, at which point irreversible tissue damage may already
have occurred. Studies from centres carrying out routine biopsies at de-
fined time-intervals have also demonstrated a significant amount
(10–30%) of rejection in the presence of unchanged renal function.
As molecular events precede the development of the immune re-
sponse, they provide an ideal opportunity to detect host responses before
significant damage to the transplant has occurred. While such changesing to Banff ‘09 classification:GSTT –Guy's and St Thomas' NHS Foundation Trust (London,
itals University NHS Foundation Trust (Canterbury, UK); Cat – Banff category; ABMR – an-
– histological features of both, ABMR and TCMR;BKVN – BK virus nephropathy (confirmed
ab induction; Inclusion and exclusion criteria for patients in categories Rejector, Stable and
les;median – themedian predicted probability from all samples of the same stable patient
tional validation.
Table 1
Inclusion and exclusion criteria for patients in the signature-development dataset.
Type Inclusion criteria Exclusion criteria
Rejector • histological features of T-cell
mediated rejection (TCMR) –
category 4 according to the Banff
‘09 criteria, evidenced in a for--
cause biopsy between days four
and 400 post transplantation;
• no preceding category 4 biopsy
or category 3 biopsy judged as
requiring treatment for rejec-
tion;
• available sample up to ten days




(ABMR and TCMR), and border-
line lesions (category 3 accord-
ing to Banff’09 criteria) - to focus
on definitive features of TCMR;
• post biopsy samples - to avoid
influence from alteration of the
immunosuppressive treatment;
• samples more than ten day
before the diagnostic biopsy – to
maximise the chances of captur-
ing an immunological response;
• ABO or HLA incompatibility;
• Alemtuzumab or Rituximab
induction
Stable • kidney transplant only – to
avoid capturing immunological
features of pancreatic rejection;
• baseline creatinine levels
reached by day seven;
• creatinine levels not exceeding
20% above the upper limit of the
normal range between days
seven and 400 post transplanta-
tion (i.e. up to 126 μmol/L in
women and 156 μmol/L in men);
• standard deviation of creatinine
between days seven and 400




transplants – to avoid isolated
subclinical pancreatic rejection;
• for-cause biopsy up to day 400
post transplantation - consid-
ered an indication of clinical
instability;
• delayed graft function and
post-transplantation dialysis;
• ABO or HLA incompatibility;
• Alemtuzumab or Rituximab
induction.
BKVN • specialised staining indicative of
BK virus nephropathy (BKVN)
performed in a for-cause biopsy
between days four and 400 post
transplantation ⁎;
• no further deterioration of graft
function after treatment for
BKVN, i.e. reduction of immuno-
suppression;
• available sample within seven
days of the diagnostic biopsy –
post-biopsy samples allowed as
immunosuppression reduction
for treatment for BKVN was
expected to show slower effect
than immunosuppression
increase for treatment of TCMR;
• Basiliximab induction
• evidence of TCMR or ABMR dur-
ing the first year post transplan-
tation;
• ABO or HLA incompatibility;
• Alemtuzumab or Rituximab
induction.
⁎ The specialised BKVN staining has become a routine procedure in more recent years,
but for the largest part of the KALIBRE study it would mainly have been be performed if a
histological differential diagnosis from TCMR was questionable.
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non-invasive samples such as peripheral blood and urine has the added
practical advantage of allowing collection of serial samples. Monitoring
of gene-expression signatures in peripheral blood and urine samples of-
fers the opportunity for surveillance of the recipient immune system
and earlier detection of acute rejection (AR), of diverse aetiology.
In fact, previous studies have identified in both, blood and urine, a
number of mRNAs associated with AR [7]. These have included mole-
cules associated with cytotoxic lymphocyte function, such as Perforin,
Granzyme B, Fas-ligand and FoxP3. Single genes, however, lack the sen-
sitivity and specificity to translate into clinical practice, and could hardly
capture the complexity of the rejection process. Technological advances
now allow reliable and cost-effective analysis of multiple genes in a sin-
gle sample. In urine, a three-gene signature of AR has been described
with an area under the curve (AUC) of 0.85 (sensitivity 79%, specificity
78%) and an increase in gene expression detected up to 20 days beforea clinically-evident AR [2]. In cardiac transplantation, the use of an 11-
gene panel has been studied and compared against the standard ap-
proach of routine biopsies. Use of the panel resulted in fewer performed
biopsies and greater patient satisfaction [3].
A critical differential diagnosis of AR is polyoma BK-virus nephropa-
thy (BKVN) [4]. This is manifested, similarly to AR, with graft dysfunc-
tion and mononuclear infiltrates in biopsy samples but, unlike AR, is
the result of immunosuppression (IS) that maybe excessive for the
requirements of the individual. Importantly, the treatment of BKVN
(reduction of IS medication) is opposite to that of AR and the definitive
diagnosis relies on a specialised immunohistochemistry staining of a
biopsy sample [5].While a reasonable inter-laboratory agreement in de-
tection of BKVN was found in a Banff quality assurance initiative [6],
focal lesionsmay become responsible for a false-negative biopsy. Taking
all evidence into account, there is still a need for an alternative non-
invasive biomarker of clinically-relevant BKVN.
In this study we have performed a comprehensive analysis in serial
peripheral blood samples from KTRs of a set of 22 candidate genes
with reported association with T-cell-mediated rejection (TCMR) in
the literature (Supplementary Table S1). We have identified a robust
gene-expression signature for TCMR and have examined longitudinally
gene expression and the effect of different anti-rejection therapies. We
subsequently tested the performance of our signature in a validation
set of patients and an independent cohort.
This information could finally provide clinicians with some insight
into the status of a recipient's immune system and be used as part of
the complex clinical management process, when deciding whether or
not to perform a biopsy and in evaluating the level of anti-rejection
therapy required by a particular individual.
2. Methods
2.1. Patients
Blood samples were collected serially from 455 consecutive KTRs,
transplanted at a single regional transplant centre (Guy's Hospital) in
theKidney Allograft Immunological Biomarkers of Rejection (KALIBRE)
study. Patients were followed up at three independent Renal units
(Guy's, King's College, and Kent & Canterbury Hospitals). Samples
were collected at 26 time-points during clinic visits over the first post-
transplant year. A total of 1464 samples from 248 patients were used
in the study, including 66 patients with an episode of rejection (Supple-
mentary Fig. S1). Patient flow-chart is shown in Fig. 1.
All patients contributing to the signature-development training
dataset (inclusion/exclusion criteria listed in Table 1) had received
treatment according to an anti-rejection protocol including Basiliximab
induction followed by maintenance therapy with Tacrolimus or Cyclo-
sporine, Mycophenolate Mofetil and Prednisolone. Histological criteria
followed the Banff ‘09 classification [8], as this was the most updated
version at the beginning of recruitment and it was maintained for con-
sistency throughout the study. Patients were categorised as Stable
(when their SCr levels were within 20% of baseline), antibody-
mediated rejection (category 2, ABMR); T-cell-mediated rejection (cat-
egory 4, TCMR); mixed rejection (histological features of both, ABMR
and TCMR) (mixed); and BK virus nephropathy (BKNV). Patient demo-
graphics are summarised in Table 2A and their immunological risk strat-
ification in Table 2B. External validation KTRs (nine rejectors, 15 non-
rejectors, one BKVN) were provided by patients from Guy's Hospital
(UK) participating in the EMPIRIKAL trial [9] (EUdraCT: 2011-000958-
30). We also included healthy controls (n = 14), previously recruited
as part of the GAMBIT study [10].
2.2. Ethics statement
Approval from research ethics committees was obtained for all in-
cluded studies: KALIBRE - Research Ethics No: 09/H0711/58; GAMBIT
Table 2A
Patient demographics. All cohorts.
Group Number patients Age at transplantation Gender Female (%) Donor type living (%) Time to biopsy (days)
Total patients used from KALIBRE study
KTRs (all) 248 47 (17–73) 92 (37) 138 (56) –
Rejectors (all) 66 48 (18–71) 25 (38) 38 (58) 68 (4–384)
Signature development patients (KALIBRE study)
Rejectors (TCMR) 27 39 (19–68) 9 (33) 16 (59) 103 (5–364)
Stable (Discovery)* 27 41 (19–70) 9 (33) 17 (63) –
BKVN* 7 54 (36–69) 1 (14) 4 (57) 195 (51–369)
Cross-sectional validation patients (KALIBRE study)
Category 1 8 42 (24–64) 2 (25) 4 (50) 87 (25–189)
Category 3 33 49 (25–73) 14 (42) 10 (30) 49 (7–196)
Category 5 10 53 (33–70) 4 (40) 5 (50) 58 (7–185)
Category 6 38 54 (18–71) 14 (37) 15 (39) 56 (6–336)
Rejectors (Mixed-type) 9 52 (24–64) 4 (44) 2 (22) 87 (5–349)
Stable (Validation)⁎ 17 43 (25–68) 5 (29) 10 (59) –
Rejectors (pre-transplantation) 18 38 (18–64) 5 (28) 16 (89) 99 (4–384)
Stable (pre-transplantation) 20 41 (19–70) 8 (40) 16 (80) –
Rejectors (Rituximab/Alemtuzumab) 10 42 (30–69) 3 (30) 10 (100) 21 (4–367)
Longitudinal validation patients (KALIBRE study)
Rejectors (TCMR + Mixed) 51 48 (18–71) 20 (39) 26 (51) 78 (4–384)
Stable (Discovery + Validation) 44 42 (19–70) 14 (32) 27 (61) –
Non-rejectors (Basiliximab) 35 46 (18–73) 14 (40) 24 (69) –
Non-rejectors (Alemtuzumab) 9 43 (36–65) 4 (44) 8 (89) –
Non-rejectors (Rituximab) 18 47 (17–72) 8 (44) 18 (100) –
External validation patients (EMPIRIKAL trial)
Rejectors (TCMR + Mixed) 9 57 (23–79) 4 (44) 0 8 (7–69)
Non-rejectors (External) 15 50 (20–76) 4 (27) 0 –
Healthy controls (GAMBIT study)
Healthy Controls 14 45 (23–72) 3 (21) – –
* Patients contributed all individual samples for longitudinal validation, while for cross-sectional comparisons and signature development contributed a summary sample withmedian
values per patient;Age at transplantation and Time to biopsy – summarisedwithmedian (minimum –maximum) per group; Longitudinal samples – covered the period betweendays
four and 400 post transplantation; Rejector – a patient with a biopsy-proven rejection; TCMR – T-cell-mediated rejection;Mixed – histological features of TCMR and antibody-mediated
rejection; Stable - patients fulfilling the inclusion/exclusion criteria in Table 1;Non-rejector – patients not fulfilling the selection criteria in Table 1 but without clinical or histological ev-
idence of TCMR, ABMR or BKVN up to day 400 post-transplantation; BKVN – patients with biopsy-proven BK-virus nephropathy fulfilling the criteria in Table 1; Biopsy categories – non-
rejection features, according to Banff’09 classification (category 1 – normal, category 3 – borderline changes, category 5 - interstitial fibrosis and tubular atrophy, category 6 – other non-
rejection histology).
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12/LO/1334. Written informed consent was obtained from all patients
participating in each of those studies.2.3. Gene-expression analysis
Peripheral blood was collected into Tempus™ Blood RNA Tubes
(Life-Technologies) and stored at−20 °C. RNA isolation, cDNA synthesis
and RT-qPCR conditions have been previously described in detail [10].
We analysed 22 genes (Supplementary Table S2a–b). Relative gene ex-
pression values were calculated with the –ΔCt method, detecting the
difference with hypoxanthine-phosphoribosyltransferase (HPRT) as a
house-keeping gene. An in-house quality control (QC) sample was in-
cluded in every analytical batch, which showed very low between-run
variability (coefficients of variation between 0·19% and 1·09%, median
0·48%). Missing data was minimal (below 0·5%).2.4. Sample size
Sample size for signature development was determined by patient
availability. We included all recipients with T-cell-mediated rejection
(TCMR) (n = 27) and BKVN (n = 7) fulfilling the inclusion/exclusion
criteria (Table 1) and the same number of stable patients (n = 27),
matched to rejectors in age, sex, and donor type, with no biopsy per-
formed and b20% SCr change after achieving baseline. Power calculation
(using an exponential approximation to estimate AUC variance) [11],
showed that with 27 patients in each group, we could estimate a 95%
confidence interval with half-width 0·103 for an expected AUC of
0·85 and with better precision for higher AUC.2.5. Statistical analysis
Statistical analysis was performed in R version 3.2.2 [12]. Non-
parametric Wilcoxon-Mann-Whitney test was used for univariate
class comparisons. Association between continuous variables was eval-
uated with Spearman correlation coefficient (r). Outliers were recoded
to the next highest or lowest value for multivariable analysis. Missing
gene-expression data were imputed with K-nearest neighbour for mi-
croarrays (impute package) [13]. Missing values were first imputed in
a 22-gene matrix of longitudinal samples, including samples collected
from day 4 to rejection in training rejectors (n = 201) and between
days 4 and 400 post-transplantation from stable patients (n=335, Sup-
plementary Fig. S2). The complete trainingmatrix was then used to im-
pute missing gene-expression for test samples, one at a time and based
only on the genes included in the examined model.
To account for the dependency of samples from the same patient, se-
rial samples were analysed with generalised linear-mixed effects
models (GLMM) with a linear, quadratic and cubic term for the fixed
and random effects of time.
To account for dependency of gene-expression on time post-
transplantation we generated time-adjusted gene-expression values,
individually for each gene, as the residuals of cubic GLMM linear regres-
sionmodels with the –ΔCt values, based on serial samples from training
stable patients (residuals for all other patients were generated using
these training models).
To develop a TCMR signature, we compared samples from TCMR re-
jectors (a single pre-rejection sample per patient, zero to nine, median:
three days pre-biopsy) and stable patients (serial samples of ten to 20,
median: 12 per patient; total: 335, summarised with the median time-
adjusted expression for each gene per patient). To develop a gene-
expression signature of BKVN, we compared BKVN-positive patients
Table 2B












Total patients used from KALIBRE study
KTRs (all) 248 26.6 56.9 16.5
Rejectors (all) 66 22.7 63.6 13.6
Signature development patients (KALIBRE study)
Rejectors (TCMR) 27 37.0 55.6 7.4
Stable (Discovery)* 27 33.3 66.7 0
BKVN* 7 14.3 85.7 0
Cross-sectional validation patients (KALIBRE study)
Category 1 8 50.0 37.5 12.5
Category 3 33 27.3 57.6 15.2
Category 5 10 30.0 60.0 10.0
Category 6 38 42.1 50.0 7.9
Rejectors (Mixed-type) 9 0 88.9 11.1
Stable (Validation)* 17 29.4 58.8 11.8
Rejectors
(Rituximab/Alemtuzumab)
10 0 60·0 40.0
Longitudinal validation patients (KALIBRE study)
Rejectors (TCMR + Mixed) 51 27.5 64.7 7.8
Stable (Validation) + Non-rejectors
(Basiliximab)
52 34.6 57.7 7.8
Non-rejectors (Basiliximab) 35 37.1 57.1 5.7
Non-rejectors (Alemtuzumab) 9 0 11.1 88.9
Non-rejectors (Rituximab) 18 0 50.0 50.0
External validation patients (EMPIRIKAL trial)
Rejectors (TCMR + Mixed) 9 N/A
Non-rejectors (External) 15 N/A
Percent of patients assigned to each immunological risk level per groupwithin the cohorts.
As per local centre protocol patients deemed to be of Low immunological riskwere: re-
cipients without HLA antibodies or recipients receiving a first transplant kidney from a
HLA identical sibling. Standard immunological risk: recipients with HLA antibodies;
and the following groups (regardless of presence or absence of HLA antibodies): Husband
to Wife, Child to Mother, Second or subsequent kidney transplant, Black recipient. High
immunological risk: recipients who are cross match negative by flow-cytometry but
who have a current or historic antibody which is directed against the new organ, and
has arisen following exposure to this antigen from a previous solid organ transplant or
pregnancy. Recipients who are cross-match positive by flow-cytometry are deemed HLA
Antibody Incompatible (HLAi) and receive Alemtuzumab (Campath®) induction and
may also undergo pre-operative antibody removal.
The induction agent for patients in the KALIBRE study was Basiliximab, unless otherwise
specified. Patients in the EMPIRIKAL study all received inductionwith Basiliximab, and 2/3
of the donor grafts would have been treated with an experimental complement inhibitor
right before transplantation (unblinding had not been available at the time of submission).
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nostic biopsy) with the combined group of TCMR rejectors and stable
patients, to secure simultaneous discrimination from non-BKVN KTRs.
To select a parsimonious gene-expression signature, i.e. the smallest
set of genes showing a satisfactory predictive performance, we used
penalised logistic regression with an elastic net penalty [14] (glmnet
package [12]). Elastic net enables gene selection by shrinking the
regression coefficients of genes statistically non-informative for dis-
crimination and, hence, retaining only genes, which are statistically-
important based on the data used in the model. For the penalty
parameters, we selected the alpha (tested in increments of 0·1),
which enabled retaining a satisfactory model performance with the
minimum number of strong predictors (i.e. those gene remainingwith-
out shrinkage at high values of alpha). The penalty parameter lambda
was optimised as themedian of 200 seven-fold cross-validation repeats
of the cv.glmnet function. The final signaturemodels were based on im-
putation, time-adjustment and elastic net regression performed in the
complete signature-development dataset.
To evaluatemodel performance,we used theAUC (95%De Long con-
fidence interval) and calculated sensitivity and specificity for a cut-off
that optimised both for TCMR and specificity only for BKVN, but
retaining sensitivity above 0·70 (pROC package) [15].
To compare the pre- and post-rejection trajectories of the probabil-
ity of TCMR in rejectors and non-rejectors, we used GLMM linearregressionwith an interaction term for group and time.We used as out-
come the predicted log-odds of rejection, which, unlike probability, has
an unrestricted continuous scale. As a reference time-point in rejectors
we used the day of the diagnostic biopsy. In non-rejectors, after demon-
strating the time-independence of the predicted probability of TCMR,
we assigned a time with respect to the reference point at random. This
ensured that the distribution of samples from non-rejectors matched
the pattern of rejectors with respect to time post-transplantation
(Supplementary Fig. S3). Samples contributing to signature develop-
ment, i.e. the 27 pre-biopsy samples for patients with TCMR and the
335 samples from the training stable patients, were excluded from the
longitudinal analysis. Although the remaining pre-rejection samples
from the 27 training rejectors were included in the imputation matrix,
they did not contribute to elastic net regression (i.e. gene selection
and regression coefficients) and, with a missingness below 0·5%, they
would not have materially influenced signature development.
2.6. Validation strategy
It should primarily be noted, that obtaining the 22 initial genes from
literature reports and not from a statistical analysis of microarrays per-
formed in our own dataset meant that our study provided a validation
dataset for already published findings.
Further, to evaluate the performance of the selected parsimonious
gene-expression signature with unseen data, we used the following
approaches:
First, we used cross-validation within the signature-development
dataset. In the cross-validation cycles all steps of signature development
(including the linear regressionmodels generating time-adjusted resid-
uals, the imputation of missing data and the elastic net regression
models performing the inherent to them gene selection (starting from
the complete list of 22 genes for each model) and the required optimi-
sation of the lambda parameter),were performedwith the training sub-
set. The left-out test subset was used solely for model validation (see
Note 1 in Supplementary Discussion for further details). A cross-
validation AUC (CV.AUC) was determined for each of 50 repeats of
seven-fold cross-validation cycles, along with sensitivity and specificity
at the fixed cut-off determined as optimal for the final signature model.
Model performancemeasures obtained in the 50 cross-validation cycles









Third, we performed validation in longitudinal samples. To test sig-
nature specificity we used the individual longitudinal samples from
the new test stable patients and also from other unseen test non-
rejectors with more compromised renal function (with or without a
for-cause biopsy during the first post-transplant year) and from non-
rejectors with alternative immunosuppression induction (the median
sample per patient participated in the cross-sectional validation). Spec-
ificity of the TCMR signature was further examined in longitudinal sam-
ples from BKVN patients. In addition, we compared serial samples from
rejectors with the combined group of the non-rejectors and the new
stable patients. Rejectors included independent test rejectors (with
TCMR and mixed-type rejection) and only the pre and post rejection
samples from the 27 training rejectors with TCMR, which were unseen
in the elastic net regression defining the signature model.
Fourth, we performed external validation with samples from inde-
pendent rejectors with TCMR features and non-rejectors from the
EMPIRIKAL trial (a pre-rejection sample for rejectors and longitudinal
samples for non-rejectors).
Fig. 2. Examples of association between gene-expression levels and time in stable patients. (a) – observed (unadjusted) –ΔCt values for IFNG, as an example of a gene with increasing
expression levels; (b) – observed (unadjusted) –ΔCt values for MARCH8, as an example of a gene with decreasing expression levels; (c) – time-adjusted gene-expression levels for
IFNG, illustrating abolition of time-dependence for gene expression; (d) – time-adjusted gene-expression levels for MARCH8; Gene expression – observed ΔCt values, relative to
hypoxanthine phosphoribosyltransferase (HPRT), in individual samples (grey dots) and a loess average curve with 95% confidence interval; Time-adjusted gene expression – fold
difference on log2 scale (same scale as gene expression), derived as the difference between the observed –ΔCt values and the predicted values using generalised linear mixed-effects
models (GLMM) linear regression, based on all serial samples (total n = 335) from the training stable kidney transplant recipients (n = 27) (a cubic relationship between gene
expression and time post transplantation was modelled for the fixed and random effects); p1, p2, p3 - p-values for the linear, quadratic and cubic fixed-effects terms for time in GLMM
(in (a) and (b) GLMMwas based on the observed –ΔCt values and the p-values confirm a statistically significant association between gene-expression and time, in (c) and (d) GLMM
was based on time-adjusted gene expression values and p-values demonstrate the time-independence of the time-adjusted gene-expression levels).
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Research data will be made available through application to the
Biobank “Transplantation, Immunology and Nephrology Tissue and In-
formation Nexus” (TIN-TIN) based at King's College London, London
UK. Provisional Ethics Ref: 17/LO/0220.Table 3
Gene-expression signatures.
Event Genes Data
TCMR All genes Training data
Cross-validation
TCMR IFNG, IP-10, ITGA4, MARCH8, RORc, Training data
SEMA7A, WDR40A Cross-validation
BKVN All genes Training data
Cross-validation
BKVN IL-15, IL1R2, MARCH8, PDCD1, Training data
TGFB, WDR40A Cross-validation
Signature-development (training) data comprised the following groups of patients defined a
viding a single sample per patient, collected between zero and nine days (median three days)
(median) of the predicted probabilities for all samples from a given patient (10 to 20 samples
BK-virus nephropathy providing a single sample per patient collected within seven days befo
from gene selection based on penalised logistic regression with elastic net penalty (Suppleme
curve with 95% DeLong confidence interval; Sens – sensitivity; Spec – specificity; Cut-offs for S
mary of model performance measures based on the predicted probabilities for unseen data ob
centile).
Highlighted in bold the most relevant AUC.2.8. Role of the funding sources
The study sponsors had no involvement in the study design, the col-
lection, analysis, and interpretation of data, in the writing of the report,
and in the decision to submit the paper for publication.AUC Sens Spec
0.96 (0.92–1.00) 0·85 0·89
0.80 (0.75–0.83) 0.67 (0.59–0.70) 0.81 (0.71–0.88)
0.95 (0.91–1.00) 0.85 0.93
0.84 (0.77–0.88) 0.67 (0.59–0.74) 0.85 (0.75–0.89)
0.93 (0.85–1.00) 0.71 0.93
0.68 (0.64–0.73) 0 (0–0.25) 0.91 (0.85–0.94)
0.95 (0.90–1.00) 0.71 0.91
0.73 (0.66–0.80) 0.43 (0·29–0.57) 0.89 (0.83–0.91)
ccording to the criteria in Table 1: Rejectors (n = 27) with T-cell mediated rejection pro-
prior to the date of the diagnostic biopsy; Stable (n = 27) patients providing a summary
per patient, median 12, total 335 samples); BKVN (n = 7) patients with biopsy-proven
re or after a diagnostic biopsy (median zero days); Gene-expression signatures resulted
ntary Fig. S5 and Fig. S11); AUC – area under the receiver operating characteristics (ROC)
ens and Spec– probability of TCMR 0·5, probability of BKVN 0·2; Cross-validation – sum-
tained in each of 50 repeats of seven-fold cross-validation cycles – median (2.5th – 97.5th
Fig. 3. Predicted probability of TCMR and kidney function in rejectors and stable or non-rejector controls and in patients with BK virus nephropathy. a –median of the set of probabilities of
T-cell-mediated rejection (TCMR) estimated for each patient of the development dataset in the 50 repeats of the cross-validation cycles (Step 12 of Note 1 in Supplementary Discussion);
(b–e) – predicted probability of TCMR, based on the newly-developed seven-gene signature (Supplementary Fig. S5); (f–k) – estimated glomerular filtration rate (eGFR), based on the
MDRD4 equation; ABMR – antibody-mediated rejection (category 2 according to Banff’09 classification); TCMR – T-cell-mediated rejection (category 4); Mixed – histological features
of both, ABMR and TCMR; TCMR+ – patients with TCMR alone and with mixed-type histology; BKVN – BK virus nephropathy (confirmed with a specialised histological staining);
Stable – patients fulfilling the inclusion and exclusion criteria listed in Table 1; Non-rejector – patient not fulfilling the selection criteria in Table 1 but without evidence of TCMR,
ABMR or BKVN up to day 400 post-transplantation; dot colour: black – rejectors, grey – stable or non-rejector patients; dot shape – induction agent in KALIBRE patients: circle –
Basiliximab, triangle – Rituximab, square – Alemtuzumab; dotted lines – cut-off 0·5 for dichotomous classification of the probability of TCMR (a-e) and median eGFR (71.8 mL/min/
1.73m2) of the summary of stable patients in the discovery signature-development dataset (F\\K); samples: rejectors – single pre-biopsy sample, BKVN – single near-biopsy sample,
stable/non-rejector patients – summary (median per patient) of longitudinal samples covering between days four and 400 post transplantation; Discovery (a,f) – training patients
used in TCMR signature development (TCMR (n = 27) fulfilling the inclusion and exclusion criteria listed in Table 1 and stable patients (n = 27)); Validation (b,g) – test patients
from the KALIBRE study used for TCMR signature validation (Mixed-type rejectors (n = 9) and new stable patients (n = 17)); External (c,h) – patients from the independent trial
EMPIRIKAL used for TSMR signature validation (rejectors (n = 9) with TCMR or Mixed-type histology, non-rejectors (n = 15)); PreTx (d,i) – cross-sectional pre-transplantation
samples – one per patient from rejectors with TCMR (n = 16) and Mixed-type (n = 2) histology and training stable patients from the signature development dataset (n = 20)); e,h –
ABMR rejectors (n = 5), RitCam rejectors with alternative induction and TCMR (n = 6) or Mixed-type histology (n = 2); BKVN patients: grey dots BKVN (n = 7) included in the
BKVN signature development dataset, crossed dots BKVN: +dot (n = 2) excluded from the training dataset due to prior suspected TCMR or some genes missing, x-dot (n = 1)
Alemtuzumab induction, x (n = 1) patient from the EMPIRICAL trial; p-values derived from a Wilcoxon-Mann-Whitney tests.
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Examining gene expression in longitudinal samples of training sta-
ble patients demonstrated high within-patient variability and system-
atic trajectory changes over the first four months post-transplantation
(Fig. 2a–b). The expression of 19 of the 22 studied genes was signifi-
cantly associatedwith time (Supplementary Table S3). After accounting
for prednisolone dose, which is systematically reduced during the first
post-transplant months (Supplementary Fig. S4), the association of
gene-expression and timewas retained, independently of prednisolone,
for 10 of the 22 genes (Supplementary Table S3), whilst eight genes
showed an association with prednisolone, independent of time. Conse-
quently, we generated time-adjusted gene-expression levels (Fig. 2c–d)
and used these in signature development. This ensured that differences
between stable patients and rejectors were accounted for by rejection
and not by time-related post-transplantation changes.
Using penalised logistic regression with elastic net penalty, we de-
veloped a parsimonious signature of TCMR, retaining seven genes
with non-zero regression coefficients and, hence, referred to as a
“seven-gene” signature (Supplementary Fig. S5/S6a/S7, Tables S4/S5),
which showed improved predictive performance in cross-validation
(CV.AUC 0.84 (0.77–0.88)) compared to the 22-gene model (Table 3,
Fig. 3a). This suggests that many of the 22 original genes contribute
more variability and noise to the 22-gene model than information facil-
itation the discrimination and, therefore, they could not be validated in
our dataset (Supplementary Fig. S5). It should also be noted that acomparison with eGFR as a diagnostic marker is not appropriate, as
SCr has been used as a selection criterion (see Note 2 in Supplementary
Discussion).
The TCMR signature showed excellent discrimination between
mixed-type rejectors and new stable patients in cross-sectional valida-
tion samples that had similar distribution of immunological risk pre-
transplant stratification (Table 2B, Fig. 3b) (AUC 0.90 (0.70–1.00)). In
the external validation dataset from the EMPIRIKAL trial, seven out of
the nine rejectors (78%) were TCMR-positive near the diagnostic biopsy
(Fig. 3c). EMPIRIKAL non-rejectors had distinctly worse kidney function
compared to KALIBRE stable patients (Fig. 3f–g vs 3h), with eight
out of 15 patients requiring dialysis in the first two weeks post-
transplantation. Nevertheless, a discrimination could be achieved from
TCMR (AUC 0.77 (0.53–1.00)). No discrimination could be achieved be-
tween TCMRand stable patients pre-transplantation (Fig. 3d) (AUC 0.57
(0.38–0.76)).
Whilst BKVN patients had low eGFR, similar to that of rejectors
(Fig. 3k), they were TCMR-negative or only weakly positive (Fig. 3e).
Five out of ten mixed-type rejectors treated with a different induction
agent were TCMR-positive near the diagnostic biopsy (Fig. 3e). Three
of the five patients with features only of ABMR in the first biopsy diag-
nostic of ARwere TCMR-positive, but the onewith the highest probabil-
ity of TCMR showed features of mixed-type rejection in a subsequent
biopsy, performed eight days after the collection of the sample shown
in Fig. 3e.
Fig. 4. Predicted probability of TCMR and kidney function in non-rejectors. (a–b) – predicted probability of T-cell-mediated rejection (TCMR), based on the newly-developed seven-gene
signature (Supplementary Fig. S5); (c–d) – estimated glomerular filtration rate (eGFR), based on the MDRD4 equation; (a,c) – cross-sectional pre-biopsy samples (up to 15 days prior
to the first post-transplantation biopsy (median two days) and a single one at 25 days) from patients which did not show features of rejection at least up to three months post biopsy;
Cat – histological category according to Banff’09 classification (Cat.1 – normal (n = 8, one (13%) TCMR-positive), Cat.3 – borderline changes (n = 33, 13 (39%) TCMR-positive),
Cat.5 – interstitial fibrosis and tubular atrophy (n = 10, three (30%) TCMR-positive), Cat.6 – other non-rejection histology (n = 38, 14 (37%) TCMR-positive)); star dots (*) – patients
with histological features of borderline changes treated for rejection due to clinical considerations; (b,d)– summary of longitudinal validation follow-up samples covering one year
post transplantation (median per patient) in non-rejectors with different induction agents (not fulfilling the strict inclusion/exclusion criteria set for stable patients in Table 1, but
without clinical or histological evidence of rejection up to day 400 post tansplantation): Basiliximab induction (n = 35, 18 with biopsy, seven (20%) TCMR-positive median),
Rituximab (n = 18, nine with biopsy, four (22%) TCMR-positive median), Alemtuzumab (n = 9, three with biopsy, six (67%) TCMR-positive median); black dots – non-rejection
biopsy during the first post-transplant year; grey dots – no biopsy; dotted lines – cut-off 0·5 for dichotomous classification of the probability of TCMR (a,b) and median eGFR (71.8
mL/min/1.73m2) (c,d) from the summary samples of the stable patients in the discovery signature-development data; p-values derived from a Wilcoxon-Mann-Whitney tests.
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eight KTRs with normal histology were TCMR-negative, but N30% of
the patients with histological features of borderline changes, chronic re-
jection or other non-rejection alterations were TCMR-positive (Fig. 4a)
and the predicted probability of TCMR was negatively correlated with
eGFR (r = −0.40, p b 0.0001)(Fig. 4c). Half of the 14 healthy controls
were TCMR-positive.
In longitudinal samples from the stable patients used for signature
development, the average predicted probability of TCMR remained con-
stant with time post-transplantation, below the cut-off, and was not in-
fluenced by adjustment for prednisolone dose (Supplementary
Fig. S8a). The probability of TCMR also remained below the cut-off for
validation stable patients and non-rejectors (Supplementary Fig. S8b).Table 4
Specificity of gene-expression signatures in longitudinal samples from non-rejection patients.
Group Patients Samples total Samples per patient* TCM
Stable Discovery 27 335 12 (10−20) 262
Stable Validation 17 85 5 65
Non-rejectors Basiliximab 35 303 8 (5–20) 216
Non-rejectors Rituximab 18 90 5 69
Non-rejectors Alemtuzumab 9 45 5 13
Non-rejectors EMPIRIKAL 15 77 5 (3–6) 43
BKVN 7 51 7 (6–10) 38
Cells – number (percentage) of longitudinal samples collected during the first post-transplant y
diated rejection (Supplementary Fig. S5); BKVN – gene-expression signature of BK-virus nephr
off of 0·5 for TCMR and 0·2 for BKVN (equivalent to specificity); Positive – predicted probabilit
TCMR and BKVN, for the same sample above/below the corresponding cut-offs; Stable – patien
promised kidney function,which either did not require a biopsy during thefirst year post transp
cell, or antibody-mediated rejection, or BKVN.Further, over the first post-transplant year, the TCMR signature demon-
strated very good specificity (above 70%) in stable patients, non-
rejectors, and BKVN patients (Table 4). Rituximab induction showed
similarity to Basiliximab induction (Fig. 4b), but TCMR-signature posi-
tivity was higher following Alemtuzumab induction (71%), despite the
comparable eGFR in alternative induction groups (Fig. 4d). Similarly,
in non-rejectors of the EMPIRIKAL trial a larger proportion of the longi-
tudinal samples were TCMR-positive (44%), with ten out of the 14 sam-
ples from the first post-transplant week being TCMR-positive.
In longitudinal samples from rejectors, the probability of TCMR in-
creased well ahead of rejection and decreased after treatment (Fig. 5a)
following kidney function and not immunosuppression changes. There
was a very clear difference between rejectors and non-rejectors at theR negative(%) BKVN negative (%) Double negative (%) Double positive (%)
(78) 264 (79) 192 (57) 1 (0)
(76) 58 (68) 41 (48) 3 (4)
(71) 234 (77) 149 (49) 2 (1)
(77) 68 (76) 51 (57) 4 (4)
(29) 15 (33) 3 (7) 20 (44)
(56) 63 (82) 31 (40) 2 (3)
(75) – – 1 (2)
ear; * –median (minimum –maximum); TCMR – gene-expression signature of T-cell-me-
opathy (six genes, Supplementary Fig. S11); negative – probability of event below the cut-
ies of event above the cut-offs;Double positive/negative – predicted probabilities of both,
ts fulfilling the criteria in Table 1; Non-rejectors - patients with a more variable and com-
lantation and, hence,were considered clinically stable, or had biopsies lacking features of T-
Fig. 5. Longitudinal evaluation of the gene-expression signature of TCMR with respect to the diagnostic biopsy. (a) – Evolution of the predicted probability of T-cell-mediated rejection
(TCMR), based on the seven-gene signature of TCMR (Supplementary Fig. S5), with time pre and post rejection: individual samples and average loess trajectories for patient groups;
Black dots – longitudinal samples from patients with TCMR: 279 samples from 41 patients (the 27 samples contributing to the signature-development dataset were excluded) and 81
samples from 10 patients with mixed-type rejection (antibody-mediated rejection (ABMR) and TCMR); Grey * – longitudinal samples from the 17 (test) stable patients included in the
validation dataset (85 samples) (fulfilling the inclusion/exclusion criteria in Table 1) and the 35 non-rejectors with Basiliximab induction (303 samples) included in the validation
dataset; Vertical line (zero days) – reference point; Reference point (time 0) – for rejectors, the day of the diagnostic biopsy (222 samples pre-biopsy (164 from TCMR and 58 from
patients with mixed-type rejection) and 138 post rejection (115 TCMR, 23 mixed-type)); for stable patients and non-rejectors time was assigned at random, such that the samples
were distributed along the timeline proportional to the number of samples from rejectors in the given week-wide time window, as well as proportional to the contribution of training
and validation stable patients, and ensuring that a single sample per patient was included in each week-wide window (240 samples before (189 non-rejectors, 51 stable) and 148
after the reference point (114 non-rejectors, 34 stable)); samples from stable patients covered the period between days 4 and 400 post transplantation; t1, t2 and t3 – p-values for the
linear, quadratic and cubic terms for time in a generalised linear mixed-effects model (GLMM) (linear regression) based on log-odds of TCMR as an outcome and including fixed
and random effects for time, a group term (stable patients as baseline), and interaction terms between time and group; g – p-value for the group term in GLMM; t1g, t2g, and t3g –
p-values for the interaction terms in GLMM; (b) – classification performance of the gene-expression signature of TCMR for weekly intervals (from 12 weeks pre to two weeks post
rejection) or fortnightly intervals (from three to eight weeks post rejection), time limited to 120 days pre and 90 days post rejection; Diamonds – area under the receiver operating
characteristics curve (AUC) for a comparison between unique samples per patient in each window (8 to 29 samples per window for rejectors (median 14, using 170 pre and 101 post-
rejection samples) and 9 to 31 samples per window for stable patients and non-rejectors (median 13, using 184 samples assigned at random to pre and 109 samples assigned to post
reference point, as described in A); Error bars – 95% DeLong confidence intervals for AUC.
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difference between the average trajectories of the two groups (Supple-
mentary Fig. S9). Discrimination between rejectors and non-rejectors
was possible for at least five weeks before and four weeks after rejec-
tion. AUC remained near or above 0.80 for the five weeks preceding re-
jection and above 0.70 for weeks six and seven (Fig. 5b). It is not a
common practice in the UK to use anti-thymocyte globuline (ATG) as
an induction agent, but 11 of the rejectors had received it as a treatment
for rejection. The probability of TCMR increased before the biopsy and
remained above 0.70 within two weeks after administration of ATG
and in some of the patients for considerably longer (Supplementary
Fig. S10).
Given the histological similarities between BKVN and TCMR and the
fact that they both represent some form of inflammation, it was impor-
tant to explore whether the genes in the TCMR signature reflect BKVN
activity. To assist differential diagnosis, we additionally developed a
parsimonious six-gene signature of BKVN (Supplementary Fig. S11/
S6b/S12, Tables S4/S5), showing (like the TCMR signature) an improvedperformance at cross-validation (CV.AUC 0.73 (0.66–0.80)) compared
to the full 22-gene model (Table 3). Only MARCH8 and WDR40A genes
were shared between the two signatures. These genes were strongly
positively correlated (r = 0·96, p b 0.0001 in the joint signature-
development group of rejectors, BKVN, and stable patients), but were
lower in TCMR compared to BKVN (Supplementary Fig. S7) and were
selected by the statistical algorithm as informative in both signatures
because the signature for BKVN was trained to discriminate BKVN
from TCMR, as well as from stable patients. Correspondingly, the signa-
tures of BKVN and TCMR were negatively correlated (r = −0.45, p b
0.0001). Notably, the majority of TCMR and mixed-type rejectors
were BKVN-negative pre-biopsy (Fig. 6a–c). The specificity of the
BKVN signature in longitudinal samples from stable patients and
non-rejectors was close or above 70% (Table 4), similarly in
Basiliximab and Rituximab-induced patients (Fig. 6g), with virtually
no double-positives for TCMR and BKVN (Table 4). On the contrary,
67% of the samples from Alemtuzumab-induced non-rejectors were
BKVN-positive and, as high as 44%, were double-positive, with only
Fig. 6. Predicted probability of BK-virus nephropathy in kidney transplant recipients. Predicted probability – (a,e) calculated as the median of the set of probabilities estimated for each
patient of the development dataset in the 50 repeats of the cross-validation cycles (Step 12 of Note 1 in Supplementary Discussion) or (b,c,d,f,g) based on the newly-developed six-gene
signature (Supplementary Fig. S11); ABMR – antibody-mediated rejection (category 2 according to Banff’09 classification); BKVN – BK virus nephropathy (confirmed with a specialised
histological staining); TCMR – T-cell-mediated rejection (category 4); Mixed – histological features of both, ABMR and TCMR; TCMR+ − patients with TCMR only or with mixed-type
histology; Stable – patients fulfilling the inclusion and exclusion criteria listed in Table 1; Non-rejector – patients not fulfilling the selection criteria in Table 1 but without clinical or
histological evidence of TCMR, ABMR or BKVN up to day 400 post-transplantation; dot colour: black – rejectors, grey – stable or non-rejector patients; dot shape - induction agent in
KALIBRE patients: circle – Basiliximab, triangle – Rituximab, square – Alemtuzumab; dotted lines - cut-off 0.2 for dichotomous classification of the probability of BKVN; samples:
rejectors - single pre-biopsy sample, BKVN –single near-biopsy sample, stable/non-rejector patients – summary (median per patients) of longitudinal samples covering between days
four and 400 post transplantation; (a) Discovery – training patients used in TCMR signature development (TCMR (n = 27) fulfilling the inclusion and exclusion criteria listed in
Table 1 and stable patients (n = 27)); (b) Validation – test patients from the KALIBRE study used for TCMR signature validation (Mixed-type rejectors (n = 9) and new stable
patients (n = 17)); (c) External – patients from the independent trial EMPIRIKAL used for TSMR signature validation (rejectors (n = 9) with TCMR or Mixed-type histology and non-
rejectors (n = 15)); (d) PreTx – cross-sectional pre-transplantation samples - one per patient from rejectors with TCMR (n = 16) and Mixed-type (n = 2) histology and training
stable patients from the signature development dataset (n = 20); (e) ABMR rejectors (n = 5), RitCam rejectors with alternative induction and TCMR (n = 6) or Mixed-type (n = 2)
histology; BKVN patients: grey dots BKVN (n = 7) included in the BKVN signature development dataset, crossed dots BKVN: +dot (n = 2) excluded from the training dataset due to
prior suspected TCMR or some genes missing, x-dot (n = 1) Alemtuzumab induction, x (n = 1) a patient from the EMPIRICAL trial; (f) – cross-sectional pre-biopsy samples (up to
15 days prior to the first post-transplantation biopsy (median two days) and a single one at 25 days) from patients which did not show features of rejection at least up to three
months post biopsy; Cat – histological category according to Banff’09 classification (Cat.1 – normal (n = 8, three (38%) BKVN-positive), Cat.3 – borderline changes (n = 33, eight
(24%) BKVN-positive), Cat.5 - interstitial fibrosis and tubular atrophy (n = 10, four (40%) BKVN-positive), Cat.6 – other non-rejection histology (n = 38, 11 (29%) BKVN-positive));
star dots (*) – patients with histological features of borderline changes treated for rejection due to clinical considerations; (g) – summary (median per patient) of longitudinal
validation follow-up samples from non-rejectors with different induction agents: Basiliximab induction (n = 35, six (17%) BKVN-positive median), Rituximab (n = 18, four (22%)
BKVN-positive), Alemtuzumab (n = 9, seven (78%) BKVN-positive median); p-values derived from a Wilcoxon-Mann-Whitney tests.
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transplantation (Fig. 6d), as well as healthy controls, were strongly
BKVN-negative.
4. Discussion
We present out the most comprehensive analysis of potential non-
invasive biomarkers of AR following kidney transplantation to date.
Notably, we have conducted longitudinal, as well as cross sectional
analysis, considering changes in gene expression over time post-
transplantation. We have also examined the effect of immunosuppres-
sive agents (type of induction agent and prednisolone reduction) and
have shown separation from BKVN, a different form of allograft inflam-
mation. We accept, however, that a limitation of our study is the rela-
tively small number of independent validation patients with TCMR,
the lack of diagnostically difficult patients and the very limited number
of BKVNpatients. It should also be noted that AR is not a simplified pres-
ent/absent condition and has various degrees of severity, so the clinical
value of AUCs and other performance measures for binary outcomes
should be evaluated with caution. Further, the number of patientswith features only of ABMR in the first biopsy diagnostic of ARwas lim-
ited, so we could not reliably evaluate whether our six-gene signature
could discriminate TCMR from ABMR, or whether it would have the
same predictive value for ABMR. However, we believe that our signa-
ture is relevant to TCMR because it includes genes that have been asso-
ciated with TCMR in completely different datasets and the statistical
algorithm was trained to discriminate TCMR from non-rejection.
Two previous similarly-sized studies have identified gene panels in
non-invasive samples to detect AR. The assessment of AR in renal trans-
plantation (AART study) involved 436 adult renal transplant recipients
from eight transplant centres in the United States (US), Spain and
Mexico and used the 17 gene panel kidney solid organ response test
(kSORT) to detect patients at high risk of AR [16]. However, this study
collected only cross-sectional samples with lower number of samples
analysed, from a heterogeneous population of both, adult and paediatric
recipients, from different countries and without a standard immuno-
suppression regimen. Given that the majority of the centres were in
the US, it is likely they received depleting antibody induction therapy.
This might explain why the statistical selection of genes for their signa-
ture did not favour any of the literature-based genes selected by the
582 S. Christakoudi et al. / EBioMedicine 41 (2019) 571–583statistical algorithm in our signature, when it is highly likely that themi-
croarrays informing gene selection in the AART study would have
contained these genes. As some of the genes involved are derived
from lymphocytes, which are killed by depleting induction therapy, it
is not surprising that we have found an effect of this therapy on our
biomarker performance. Potentially, differences in the statistical ap-
proaches for selection may have also contributed to the lack of overlap.
The CTOT-04 study collected serial urine samples from 485 recipients
from multiple centres across the US, and identified a three-gene signa-
ture predictive of AR [2]. However, the study highlighted the difficulty
of QC of urine samples. Analysis of urine is not possible inmany patients
with delayed graft function and anuria. This signature was also positive
in BKVN.
Our study is the only one to date to demonstrate and display the pro-
nounced within-patient gene-expression variability, systematic
changes post-transplantation and association with prednisolone dose.
It also uniquely examines individual patient trajectories. Our QC sam-
ples demonstrated very low between-batch variability, indicating that
the high within-person variability is driven by biological, rather than
analytical factors. TCMR-positivity in non-rejectors with poorer kidney
function was similar to that in stable KTRs with good kidney function
(Table 4), illustrating that our TCMR signature provides information
on the underlying immunological response, independent of kidney
function. Further, half of the samples from healthy controls, expected
to show vigilant immunological response to everyday environmental
triggers, were TCMR-positive, indicating an association of our TCMR sig-
nature with active host-defence mechanisms.
Evidence that the TCMR signature genes reflect pro-inflammatory
immunological pathways stems from the fact that IFNG and IP10, both
coding cytokines generated after Th1-cell activation [17], were
up-regulated in TCMR (Supplementary Fig. S5). Further, SEMA7A gene,
included in the Allomap signature of cardiac AR [18] and strongly nega-
tively associated with heart function [19], showed the highest positive
regression coefficient, equivalent to the largest fold-increase in TCMR
(Supplementary Fig. S5). Its product Sema7A, a membrane bound
semaphorine, is a potent pro-inflammatory monocyte [20] and macro-
phage stimulator [21].
Our signature emerges four weeks earlier than that shown by a
three-gene urine-based signature of TCMR [2], which shares with our
signature IP10 up-regulation. Similarly Perforin, GranzymeB, CXCR3 and
TGFBwere statistically excluded as not relevant to TCMR discrimination
(Supplementary Fig. S5). A criticism of the three-gene signature has
been the lack of discrimination fromBKVN [22].We, however, addition-
ally provide a six-gene BKVN signature, negatively associated with the
predicted probability of TCMR, to complement the differential diagnosis
(Supplementary Fig. S11). Only in the case of Alemtuzumab induction
there was high positivity for both, TCMR and BKVN (Table 4), the
latter likely stemming from the vigorous immunosuppression. All
healthy controls and KTRs pre-transplantation (Fig. 6d) were strongly
BKVN-negative, further supporting that our BKVN signature reflects
BKV activation kept tightly under control in individuals without
immunosuppression.
In support of a mechanistic involvement of BKVN signature-genes
(Supplementary Fig. S11) in the immune response to viral pathogens,
TGFB gene expression in peripheral blood mononuclear cells and trans-
plants has been found positively associatedwith BKV viremia and BKVN
in KTRs [23–25]. Further, IL15 gene, the product of which is instrumen-
tal to NK-cell activation in response to viral infections [26] and is impli-
cated in the expansion of BKV-specific T-cells [27], has been reported as
downregulated in human endothelial cells infected with BKV [28]. In
addition, MARCH8, has been identified as an antiviral factor involved
in reduction of viral infectivity, with high expression in monocyte-
derived macrophages [29]. Nevertheless, our BKVN signature would
need further validation in a larger BKVN dataset.
While not able to replace the present biopsies as a gold standard to
confirm AR, our panel may have a role in serial monitoring, providingthe clinician with valuable extra information on immune system status
to help manage KTRs. Serial monitoring with biopsies remains a high-
risk, costly and impractical strategy. Clinical decision-making post-
transplantation is complex and utilises a number of factors to determine
a particular course of action, and this should remain the case. Potential
clinical applications of our test could refine better the patients that
may need a biopsy, it could include earlier detection and treatment of
AR through earlier biopsy, help in interpretation of cases where the bi-
opsy is reported as “borderline”, detection of sub-clinical rejection in a
biopsy where there is no evidence of graft dysfunction based on SCr
and separation of other causes of graft dysfunction such as BKVN. The
panel could also be used to detect patients at low risk of rejection,
thereby allowing reduction of immunosuppression, thus minimising
side effects. Further prospective analysis is now required to determine
whether or not the use of such a test can improve clinical outcomes.
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